Skip to main content
Top
Published in: Tumor Biology 12/2014

01-12-2014 | Research Article

The genetic association between pri-miR-34b/c polymorphism (rs4938723 T > C) and susceptibility to cancers: evidence from published studies

Published in: Tumor Biology | Issue 12/2014

Login to get access

Abstract

Recently, several molecular epidemiological studies have focused on the association between pri-miR-34b/c rs4938723 SNP and the susceptibility to different cancers. Due to the controversial rather than conclusive results, we performed this meta-analysis to assess more precise and comprehensive conclusion about the association. Data published until July 2014 were collected from PubMed, Embase, Web of Science, Chinese National Knowledge Infrastructure, Wanfang Data, Chinese BioMedical Literature Database, and VIP database of Chinese Journal. Ultimately, 13 articles with a total of 7,753 cases and 8,014 controls were considered eligible for inclusion. The odds ratio (OR) and its 95 % confidence interval (95%CI) were used to assess the strength of association. In the overall analysis, a significant association between pri-miR-34b/c rs4938723 polymorphism and increased cancer susceptibility was found in heterozygous model (TC vs. TT: OR = 1.148, 95%CI 1.034–1.275, P = 0.010) and dominant model (CC + TC vs. TT: OR =1.166, 95%CI 1.028–1.322, P = 0.017). In subgroup analysis of ethnicity, pri-miR-34b/c rs4938723 polymorphism was significantly associated with an increased cancer susceptibility for Asian population in heterozygous model (TC vs. TT: OR = 1.169, 95%CI 1.031–1.326, P = 0.015) and dominant model (CC + TC vs. TT: OR = 1.185, 95%CI 1.017–1.382, P = 0.030), whereas no significant association for Caucasian population was observed in any genetic models. Intriguingly, stratified analysis revealed opposite results that pri-miR-34b/c polymorphism contributed to susceptibility to hepatocellular carcinoma while reduced susceptibility to colorectal cancer and esophageal squamous cell cancer in Asians. Considering some limitation of our meta-analysis, future well-designed case-control studies with larger sample sizes are required to confirm our findings.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ambros V. The functions of animal microRNAs. Nature. 2004;431:350–5. Ambros V. The functions of animal microRNAs. Nature. 2004;431:350–5. 
2.
go back to reference Babashah S, Soleimani M. The oncogenic and tumour suppressive roles of microRNAs in cancer and apoptosis. Eur J Cancer. 2011;47:1127–37.CrossRef Babashah S, Soleimani M. The oncogenic and tumour suppressive roles of microRNAs in cancer and apoptosis. Eur J Cancer. 2011;47:1127–37.CrossRef
3.
go back to reference Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857–66.CrossRef Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857–66.CrossRef
4.
go back to reference Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microrna targets. Cell. 2005;120:15–20.CrossRef Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microrna targets. Cell. 2005;120:15–20.CrossRef
5.
go back to reference Saunders MA, Liang H, Li WH. Human polymorphism at micrornas and microrna target sites. Proc Natl Acad Sci U S A. 2007;104:3300–5.CrossRef Saunders MA, Liang H, Li WH. Human polymorphism at micrornas and microrna target sites. Proc Natl Acad Sci U S A. 2007;104:3300–5.CrossRef
6.
go back to reference He B, Pan Y, Cho WC, Xu Y, Gu L, Nie Z, et al. The association between four genetic variants in micrornas (rs11614913, rs2910164, rs3746444, rs2292832) and cancer risk: evidence from published studies. PLoS One. 2012;7:e49032.CrossRef He B, Pan Y, Cho WC, Xu Y, Gu L, Nie Z, et al. The association between four genetic variants in micrornas (rs11614913, rs2910164, rs3746444, rs2292832) and cancer risk: evidence from published studies. PLoS One. 2012;7:e49032.CrossRef
7.
go back to reference Wang F, Sun G, Zou Y, Li Y, Hao L, Pan F. Association of microrna-499 rs3746444 polymorphism with cancer risk: evidence from 7188 cases and 8548 controls. PLoS One. 2012;7:e45042.CrossRef Wang F, Sun G, Zou Y, Li Y, Hao L, Pan F. Association of microrna-499 rs3746444 polymorphism with cancer risk: evidence from 7188 cases and 8548 controls. PLoS One. 2012;7:e45042.CrossRef
8.
go back to reference Srivastava K, Srivastava A. Comprehensive review of genetic association studies and meta-analyses on mirna polymorphisms and cancer risk. PLoS One. 2012;7:e50966.CrossRef Srivastava K, Srivastava A. Comprehensive review of genetic association studies and meta-analyses on mirna polymorphisms and cancer risk. PLoS One. 2012;7:e50966.CrossRef
9.
go back to reference Qiu MT, Hu JW, Ding XX, Yang X, Zhang Z, Yin R, et al. Hsa-mir-499 rs3746444 polymorphism contributes to cancer risk: a meta-analysis of 12 studies. PLoS One. 2012;7:e50887.CrossRef Qiu MT, Hu JW, Ding XX, Yang X, Zhang Z, Yin R, et al. Hsa-mir-499 rs3746444 polymorphism contributes to cancer risk: a meta-analysis of 12 studies. PLoS One. 2012;7:e50887.CrossRef
10.
go back to reference Li L, Wu J, Sima X, Bai P, Deng W, Deng X, et al. Interactions of mir-34b/c and tp-53 polymorphisms on the risk of nasopharyngeal carcinoma. Tumour Biol J Int Soc Oncodev Biol Med. 2013;34:1919–23.CrossRef Li L, Wu J, Sima X, Bai P, Deng W, Deng X, et al. Interactions of mir-34b/c and tp-53 polymorphisms on the risk of nasopharyngeal carcinoma. Tumour Biol J Int Soc Oncodev Biol Med. 2013;34:1919–23.CrossRef
11.
go back to reference Xu Y, Liu L, Liu J, Zhang Y, Zhu J, Chen J, et al. A potentially functional polymorphism in the promoter region of mir-34b/c is associated with an increased risk for primary hepatocellular carcinoma. Int J Cancer J Int Cancer. 2011;128:412–7.CrossRef Xu Y, Liu L, Liu J, Zhang Y, Zhu J, Chen J, et al. A potentially functional polymorphism in the promoter region of mir-34b/c is associated with an increased risk for primary hepatocellular carcinoma. Int J Cancer J Int Cancer. 2011;128:412–7.CrossRef
12.
go back to reference Tian Q, Jia J, Ling S, Liu Y, Yang S, Shao Z. A causal role for circulating mir-34b in osteosarcoma. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2014;40:67–72. Tian Q, Jia J, Ling S, Liu Y, Yang S, Shao Z. A causal role for circulating mir-34b in osteosarcoma. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2014;40:67–72.
13.
go back to reference Gao LB, Li LJ, Pan XM, Li ZH, Liang WB, Bai P, et al. A genetic variant in the promoter region of mir-34b/c is associated with a reduced risk of colorectal cancer. Biol Chem. 2013;394:415–20.CrossRef Gao LB, Li LJ, Pan XM, Li ZH, Liang WB, Bai P, et al. A genetic variant in the promoter region of mir-34b/c is associated with a reduced risk of colorectal cancer. Biol Chem. 2013;394:415–20.CrossRef
14.
go back to reference Yin J, Wang X, Zheng L, Shi Y, Wang L, Shao A, et al. Hsa-mir-34b/c rs4938723 t>c and hsa-mir-423 rs6505162 c>a polymorphisms are associated with the risk of esophageal cancer in a Chinese population. PLoS One. 2013;8:e80570.CrossRef Yin J, Wang X, Zheng L, Shi Y, Wang L, Shao A, et al. Hsa-mir-34b/c rs4938723 t>c and hsa-mir-423 rs6505162 c>a polymorphisms are associated with the risk of esophageal cancer in a Chinese population. PLoS One. 2013;8:e80570.CrossRef
15.
go back to reference Son MS, Jang MJ, Jeon YJ, Kim WH, Kwon CI, Ko KH, et al. Promoter polymorphisms of pri-mir-34b/c are associated with hepatocellular carcinoma. Gene. 2013;524:156–60.CrossRef Son MS, Jang MJ, Jeon YJ, Kim WH, Kwon CI, Ko KH, et al. Promoter polymorphisms of pri-mir-34b/c are associated with hepatocellular carcinoma. Gene. 2013;524:156–60.CrossRef
16.
go back to reference Zhang J, Huang X, Xiao J, Yang Y, Zhou Y, Wang X, et al. Pri-mir-124 rs531564 and pri-mir-34b/c rs4938723 polymorphisms are associated with decreased risk of esophageal squamous cell carcinoma in Chinese populations. PLoS One. 2014;9:e100055.CrossRef Zhang J, Huang X, Xiao J, Yang Y, Zhou Y, Wang X, et al. Pri-mir-124 rs531564 and pri-mir-34b/c rs4938723 polymorphisms are associated with decreased risk of esophageal squamous cell carcinoma in Chinese populations. PLoS One. 2014;9:e100055.CrossRef
17.
go back to reference Zhang S, Qian J, Cao Q, Li P, Wang M, Wang J, et al. A potentially functional polymorphism in the promoter region of mir-34b/c is associated with renal cell cancer risk in a Chinese population. Mutagenesis. 2014;29:149–54.CrossRef Zhang S, Qian J, Cao Q, Li P, Wang M, Wang J, et al. A potentially functional polymorphism in the promoter region of mir-34b/c is associated with renal cell cancer risk in a Chinese population. Mutagenesis. 2014;29:149–54.CrossRef
18.
go back to reference Hermeking H. The mir-34 family in cancer and apoptosis. Cell Death Differ. 2010;17:193–9.CrossRef Hermeking H. The mir-34 family in cancer and apoptosis. Cell Death Differ. 2010;17:193–9.CrossRef
19.
go back to reference Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, et al. P53-mediated activation of mirna34 candidate tumor-suppressor genes. Curr Biol CB. 2007;17:1298–307.CrossRef Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, et al. P53-mediated activation of mirna34 candidate tumor-suppressor genes. Curr Biol CB. 2007;17:1298–307.CrossRef
20.
go back to reference Han Y, Pu R, Han X, Zhao J, Zhang Y, Zhang Q, et al. Associations of pri-mir-34b/c and pre-mir-196a2 polymorphisms and their multiplicative interactions with hepatitis b virus mutations with hepatocellular carcinoma risk. PLoS One. 2013;8:e58564.CrossRef Han Y, Pu R, Han X, Zhao J, Zhang Y, Zhang Q, et al. Associations of pri-mir-34b/c and pre-mir-196a2 polymorphisms and their multiplicative interactions with hepatitis b virus mutations with hepatocellular carcinoma risk. PLoS One. 2013;8:e58564.CrossRef
21.
go back to reference Oh J, Kim JW, Lee BE, Jang MJ, Chong SY, Park PW, et al. Polymorphisms of the pri-mir-34b/c promoter and tp53 codon 72 are associated with risk of colorectal cancer. Oncol Rep. 2014;31:995–1002.CrossRef Oh J, Kim JW, Lee BE, Jang MJ, Chong SY, Park PW, et al. Polymorphisms of the pri-mir-34b/c promoter and tp53 codon 72 are associated with risk of colorectal cancer. Oncol Rep. 2014;31:995–1002.CrossRef
22.
go back to reference Bensen JT, Tse CK, Nyante SJ, Barnholtz-Sloan JS, Cole SR, Millikan RC. Association of germline microrna snps in pre-mirna flanking region and breast cancer risk and survival: the Carolina breast cancer study. Cancer Causes Control CCC. 2013;24:1099–109.CrossRef Bensen JT, Tse CK, Nyante SJ, Barnholtz-Sloan JS, Cole SR, Millikan RC. Association of germline microrna snps in pre-mirna flanking region and breast cancer risk and survival: the Carolina breast cancer study. Cancer Causes Control CCC. 2013;24:1099–109.CrossRef
23.
go back to reference Jamroziak K, Szemraj J, Rawstron A, Szemraj-Rogucka Z, Grzybowska-Izydorczyk O, Giannopoulos K, et al. Polymorphisms of mir-34b/c, mir-146a and mir-196a-2 and predisposition to chronic lymphocytic leukemia and monoclonal b-cell lymphocytosis. Blood. 2011;118:4585. Jamroziak K, Szemraj J, Rawstron A, Szemraj-Rogucka Z, Grzybowska-Izydorczyk O, Giannopoulos K, et al. Polymorphisms of mir-34b/c, mir-146a and mir-196a-2 and predisposition to chronic lymphocytic leukemia and monoclonal b-cell lymphocytosis. Blood. 2011;118:4585.
24.
go back to reference Rozan LM, El-Deiry WS. P53 downstream target genes and tumor suppression: a classical view in evolution. Cell Death Differ. 2007;14:3–9.CrossRef Rozan LM, El-Deiry WS. P53 downstream target genes and tumor suppression: a classical view in evolution. Cell Death Differ. 2007;14:3–9.CrossRef
25.
go back to reference Hollstein M, Sidransky D, Vogelstein B. CC H: P53 mutations in human cancers. Science. 1991;253:49–53.CrossRef Hollstein M, Sidransky D, Vogelstein B. CC H: P53 mutations in human cancers. Science. 1991;253:49–53.CrossRef
26.
go back to reference He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, et al. A microrna component of the p53 tumour suppressor network. Nature. 2007;447:1130–4.CrossRef He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, et al. A microrna component of the p53 tumour suppressor network. Nature. 2007;447:1130–4.CrossRef
27.
go back to reference Vogt M, Munding J, Gruner M, Liffers ST, Verdoodt B, Hauk J, et al. Frequent concomitant inactivation of mir-34a and mir-34b/c by cpg methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Virchows Arch Int J Pathol. 2011;458:313–22.CrossRef Vogt M, Munding J, Gruner M, Liffers ST, Verdoodt B, Hauk J, et al. Frequent concomitant inactivation of mir-34a and mir-34b/c by cpg methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Virchows Arch Int J Pathol. 2011;458:313–22.CrossRef
28.
go back to reference Deng G, Kakar S, Kim YS. Microrna-124a and microrna-34b/c are frequently methylated in all histological types of colorectal cancer and polyps, and in the adjacent normal mucosa. Oncol Lett. 2011;2:175–80.CrossRef Deng G, Kakar S, Kim YS. Microrna-124a and microrna-34b/c are frequently methylated in all histological types of colorectal cancer and polyps, and in the adjacent normal mucosa. Oncol Lett. 2011;2:175–80.CrossRef
29.
go back to reference Toyota M, Suzuki H, Sasaki Y, Maruyama R, Imai K, Shinomura Y, et al. Epigenetic silencing of microrna-34b/c and b-cell translocation gene 4 is associated with cpg island methylation in colorectal cancer. Cancer Res. 2008;68:4123–32.CrossRef Toyota M, Suzuki H, Sasaki Y, Maruyama R, Imai K, Shinomura Y, et al. Epigenetic silencing of microrna-34b/c and b-cell translocation gene 4 is associated with cpg island methylation in colorectal cancer. Cancer Res. 2008;68:4123–32.CrossRef
30.
go back to reference Suzuki R, Yamamoto E, Nojima M, Maruyama R, Yamano HO, Yoshikawa K, et al. Aberrant methylation of microrna-34b/c is a predictive marker of metachronous gastric cancer risk. J Gastroenterol. 2014;49:1135–44. Suzuki R, Yamamoto E, Nojima M, Maruyama R, Yamano HO, Yoshikawa K, et al. Aberrant methylation of microrna-34b/c is a predictive marker of metachronous gastric cancer risk. J Gastroenterol. 2014;49:1135–44.
31.
go back to reference Muraoka T, Soh J, Toyooka S, Aoe K, Fujimoto N, Hashida S, et al. The degree of microrna-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma. Lung Cancer. 2013;82:485–90.CrossRef Muraoka T, Soh J, Toyooka S, Aoe K, Fujimoto N, Hashida S, et al. The degree of microrna-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma. Lung Cancer. 2013;82:485–90.CrossRef
32.
go back to reference Wang LG, Ni Y, Su BH, Mu XR, Shen HC, Du JJ. Microrna-34b functions as a tumor suppressor and acts as a nodal point in the feedback loop with met. Int J Oncol. 2013;42:957–62.CrossRef Wang LG, Ni Y, Su BH, Mu XR, Shen HC, Du JJ. Microrna-34b functions as a tumor suppressor and acts as a nodal point in the feedback loop with met. Int J Oncol. 2013;42:957–62.CrossRef
33.
go back to reference Dong F. Lou D: microrna-34b/c suppresses uveal melanoma cell proliferation and migration through multiple targets. Mol Vis. 2012;18:537–46.PubMedPubMedCentral Dong F. Lou D: microrna-34b/c suppresses uveal melanoma cell proliferation and migration through multiple targets. Mol Vis. 2012;18:537–46.PubMedPubMedCentral
34.
go back to reference Kubo T, Toyooka S, Tsukuda K, Sakaguchi M, Fukazawa T, Soh J, et al. Epigenetic silencing of microrna-34b/c plays an important role in the pathogenesis of malignant pleural mesothelioma. Clin Cancer Res Off J Am Assoc Cancer Res. 2011;17:4965–74.CrossRef Kubo T, Toyooka S, Tsukuda K, Sakaguchi M, Fukazawa T, Soh J, et al. Epigenetic silencing of microrna-34b/c plays an important role in the pathogenesis of malignant pleural mesothelioma. Clin Cancer Res Off J Am Assoc Cancer Res. 2011;17:4965–74.CrossRef
35.
go back to reference Svoboda M, Sana J, Redova M, Navratil J, Palacova M, Fabian P, et al. Mir-34b is associated with clinical outcome in triple-negative breast cancer patients. Diagn Pathol. 2012;7:31.CrossRef Svoboda M, Sana J, Redova M, Navratil J, Palacova M, Fabian P, et al. Mir-34b is associated with clinical outcome in triple-negative breast cancer patients. Diagn Pathol. 2012;7:31.CrossRef
36.
go back to reference Liu C, Cheng H, Shi S, Cui X, Yang J, Yu X, et al. Microrna 34b inhibits pancreatic cancer metastasis through repressing smad3. Curr Mol Med. 2013;13:467–78.CrossRef Liu C, Cheng H, Shi S, Cui X, Yang J, Yu X, et al. Microrna 34b inhibits pancreatic cancer metastasis through repressing smad3. Curr Mol Med. 2013;13:467–78.CrossRef
37.
go back to reference Bartel DP. Micrornas: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.CrossRef Bartel DP. Micrornas: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.CrossRef
38.
go back to reference Bossard P, Zaret KS. Gata transcription factors as potentiators of gut endoderm differentiation. Development. 1998;125:4909–17.CrossRef Bossard P, Zaret KS. Gata transcription factors as potentiators of gut endoderm differentiation. Development. 1998;125:4909–17.CrossRef
39.
go back to reference Chou J, Provot S, Werb Z. Gata3 in development and cancer differentiation: cells gata have it! J Cell Physiol. 2010;222:42–9.CrossRef Chou J, Provot S, Werb Z. Gata3 in development and cancer differentiation: cells gata have it! J Cell Physiol. 2010;222:42–9.CrossRef
40.
go back to reference Liang T-J, Liu H-J, Zhao X-Q, Yu C-H, Li C-S. Lack of association of mir-34b/c polymorphism (rs4938723) with hepatocellular carcinoma: a meta-analysis. PLoS One. 2013;8:e68588.CrossRef Liang T-J, Liu H-J, Zhao X-Q, Yu C-H, Li C-S. Lack of association of mir-34b/c polymorphism (rs4938723) with hepatocellular carcinoma: a meta-analysis. PLoS One. 2013;8:e68588.CrossRef
41.
go back to reference Wang Z, Wu J, Zhang G, Cao Y, Jiang C, Ding Y. Associations of mir-499 and mir-34b/c polymorphisms with susceptibility to hepatocellular carcinoma: an evidence-based evaluation. Gastroenterol Res Pract. 2013;2013:719202.PubMedPubMedCentral Wang Z, Wu J, Zhang G, Cao Y, Jiang C, Ding Y. Associations of mir-499 and mir-34b/c polymorphisms with susceptibility to hepatocellular carcinoma: an evidence-based evaluation. Gastroenterol Res Pract. 2013;2013:719202.PubMedPubMedCentral
42.
go back to reference Sun Q, Gu H, Zeng Y, Xia Y, Wang Y, Jing Y, et al. Hsa-mir-27a genetic variant contributes to gastric cancer susceptibility through affecting mir-27a and target gene expression. Cancer Sci. 2010;101:2241–7.CrossRef Sun Q, Gu H, Zeng Y, Xia Y, Wang Y, Jing Y, et al. Hsa-mir-27a genetic variant contributes to gastric cancer susceptibility through affecting mir-27a and target gene expression. Cancer Sci. 2010;101:2241–7.CrossRef
43.
go back to reference Shi D, Li P, Ma L, Zhong D, Chu H, Yan F, et al. A genetic variant in pre-mir-27a is associated with a reduced renal cell cancer risk in a chinese population. PLoS One. 2012;7:e46566.CrossRef Shi D, Li P, Ma L, Zhong D, Chu H, Yan F, et al. A genetic variant in pre-mir-27a is associated with a reduced renal cell cancer risk in a chinese population. PLoS One. 2012;7:e46566.CrossRef
44.
go back to reference Chen X, Hu H, Guan X, Xiong G, Wang Y, Wang K, et al. Cpg island methylation status of mirnas in esophageal squamous cell carcinoma. Int J Cancer. 2012;130:1607–13.CrossRef Chen X, Hu H, Guan X, Xiong G, Wang Y, Wang K, et al. Cpg island methylation status of mirnas in esophageal squamous cell carcinoma. Int J Cancer. 2012;130:1607–13.CrossRef
Metadata
Title
The genetic association between pri-miR-34b/c polymorphism (rs4938723 T > C) and susceptibility to cancers: evidence from published studies
Publication date
01-12-2014
Published in
Tumor Biology / Issue 12/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2572-y

Other articles of this Issue 12/2014

Tumor Biology 12/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine